Cambridge, UK, 19 June 2020 - OKRA, a leading provider of Artificial Intelligence (AI) driven analytics for Life Sciences, today hit an important milestone, delivering 2 million validated predictions so far in 2020, smashing through its yearly target in just half the expected time. This underscores OKRA’s achievements in empowering the pharmaceutical industry with explainable, real-time AI solutions.
London – Arena International announced today the first-ever Direct-to-Patient and Virtual Clinical Trials (https://arena-international.com/dtpvirtual/) will be held as a Digital Experience on Thursday, 9 July 2020. As COVID-19 has forced the market to move towards decentralized and remote models, this event provides the perfect opportunity for clinical trial professionals to hear, meet and learn from top-class speakers around the world to discuss challenges and innovations in this critical time.
Chadds Fords, PA, June 5 2020: MOBILion Systems, Inc. is showcasing its first ion mobility separations product to the biopharma drug development and academic research markets, with data from its first beta users, during the American Society for Mass Spectrometry’s (ASMS) virtual conference.
Houston, TX (May 2020) – Pulmotect, Inc., a clinical-stage biotechnology company, has received approval from the U.S. Food & Drug Administration (FDA) to initiate two COVID-19 Phase-2 clinical trials of its innate immune-stimulating drug PUL-042. The Company plans to start accrual within the next week at up to twenty U.S. sites. The trials are for the prevention of infection with SARS-CoV-2 and the prevention of disease progression in patients with early COVID-19 disease. Funding for the trials came from the final closing of the Company’s offering of Series B Preferred stock in March.
In a recent study published in Nature Communications, scientists from Cornell University made new findings in common and fatal gastric cancer research. In the United States, the incidence of gastroesophageal cancer increased 2.5-fold from the 1970s to the early 2000s, however, from the 1950s, the number of all patients with gastric cancer decreased by more than 80%; despite this, gastric cancer is still the fifth most common cancer and the third leading cause of cancer death worldwide.